NASDAQ · Drug Manufacturers - Specialty & Generic · USD

BGM Group Ltd. (BGM) Stock Analysis

BGM Group Ltd. (BGM) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BGM

$8.24

−$0.73 (−8.14%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BGM with… →

BGM Key Statistics

As of Oct 21, 2026

Trading

Open: $8.24
Previous Close: $8.97
52-Week Range: 6.45–303.00
Volume: 1.17K

Valuation

Market Cap: $119.79M
P/E Ratio: unprofitable
P/S ratio: 2.50
EPS (ttm): −4.80

Financials (FY)

Revenue (FY): $37.92M+51.09%
Net Income (FY): −$19.94M
Profit margin: −44.22%
Shares Outstanding: 12.69M
1-Year Return: −13.45%

Dividend and dates

Avg Volume: 6.40K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BGM closed at $8.24, −13.45% over 1 year.

BGM Group Ltd. (BGM) has a market capitalization of $119.79M.

In fiscal 2025, BGM reported revenue of $37.92M.

BGM Stock Return by Calendar Year

BGM Group Ltd. (BGM) return since Jan 2021: what $10,000 became

1 year: $10,000 $8,655; −13.45%
5 years: $10,000 $4,362; −56.38%
Since Jan 2021: $10,000 $1,698; −83.02%

If you had invested $10,000 in BGM Group Ltd. (BGM) at the close on January 12, 2021, the earliest close on record here, it would have been worth $1,698 at the close on October 21, 2026: −83.02% in total, −26.45% a year, with dividends reinvested, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−73.50%−72.11%+7.51%+119.20%−56.33%+123.31%

202120222023202420252026*

Year	Return
2026 (partial year)	+123.31%
2025	−56.33%
2024	+119.20%
2023	+7.51%
2022	−72.11%
2021	−73.50%

As of October 21, 2026.

BGM Revenue and Earnings by Fiscal Year

FY ends September

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$37.92M	−$19.94M	−52.6%
2024	$25.10M	−$1.44M	−5.7%
2023	$46.47M	−$7.78M	−16.7%
2022	$64.86M	$1.08M	1.7%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$37.92M	$6.31M	−$12.45M	−$19.94M	−52.6%
2024	$25.10M	$4.11M	−$357.36K	−$1.44M	−5.7%
2023	$46.47M	$1.75M	−$2.42M	−$7.78M	−16.7%
2022	$64.86M	$6.23M	$2.52M	$1.08M	1.7%

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

BGM Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks

Metric	BGM	Drug Manufacturers - Specialty & Generic median	vs median
P/S ratio	2.50	2.10	19% above
Profit margin	−44.22%	−8.14%	36.1 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

BGM Group Ltd. (BGM) is capitalised at $119.79M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector.

BGM last closed at $8.24 on October 21, 2026. That is −$0.73 (−8.14%) against the previous close. Over the past 52 weeks the price has ranged from $6.45 to $303.00. The latest close sits 27.75% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $37.92M. That is +51.09% against the prior fiscal year, when revenue was $25.10M. The same year closed with a net loss of $19.94M. The reported profit margin is −44.22%. That is 36.1 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are −4.8.

Across the 4 fiscal years on file, revenue moves from $64.86M in 2022 to $37.92M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 2.5 times revenue. On price-to-sales that is 19.08% above the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −13.45%. Across 5 years the annualized return works out at −15.29%. Annualized volatility over the trailing 5 years is 1,351.81%.

Growth & Income

The dividend record for BGM runs through 2023.

The strongest complete calendar year on file is 2024 at +119.20%; the weakest is 2021 at −73.50%. Of the 5 complete calendar years on file, 2 finished higher. So far in 2026 the total return is +123.31%.

Peer Comparison

BGM Group Ltd. (BGM) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
BGM Group Ltd.	BGM	$119.79M	—
Takeda Pharmaceutical Company Limited	TAK	$63.67B	—
Teva Pharmaceutical Industries Limited	TEVA	$47.37B	67.7
Haleon plc	HLN	$44.06B	20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. BGM Group Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

TEVA

Teva Pharmaceutical Industries Limited

$47.37B

HLN

Haleon plc

$44.06B

ZTS

Zoetis Inc.

$32.90B

UTHR

United Therapeutics Corporation

$24.17B

VTRS

Viatris Inc.

$21.19B

View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About BGM Group Ltd.

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.

Visit website →